Pharmaceutical regulatory data, drug approvals & compliance tracking
Home › Drug Approvals › Rare Diseases
Access detailed information about rare diseases drug approvals. FDA News aggregates data from multiple verified sources to provide actionable insights. The data presented covers key metrics, trends, and comparative analysis across multiple dimensions. Users can leverage this information for research, benchmarking, and strategic decision-making.
Data accuracy is our top priority. We employ automated quality checks and manual review processes to maintain the highest standards. If you notice any discrepancies, please report them through our feedback form. Regional variations can significantly impact the numbers shown. We recommend filtering by your specific geography for the most relevant insights. Our coverage spans major markets worldwide.
Updated regularly with the latest available data. Bookmark this page for easy access to current information. Sign up for our newsletter to receive updates directly.
| Drug Name | Manufacturer | Approval Date | Indication | Type |
|---|---|---|---|---|
| Rarexumab | PharmaCo A | Mar 2026 | Advanced rare diseases | Biologic |
| Raretinib | PharmaCo B | Jan 2026 | Relapsed rare diseases | Small molecule |
| Rarelizumab | PharmaCo C | Nov 2025 | Moderate rare diseases | Monoclonal Ab |
| Rarestat | PharmaCo D | Sep 2025 | Chronic rare diseases | Oral |
| Rareparin | PharmaCo E | Jul 2025 | Acute rare diseases | Injectable |
Data updated continuously. Last refresh: May 11, 2026 14:30 UTC.
